These dysfunctions include (i) insulin resistance and an increase in insulin-like growth factor 1, (ii) elevated adipokines secreted from visceral adipocytes, and (iii) free fatty acids and aromatase activity; these all collectively attribute to MetS and furthermore NAFLD [50]. This evidence concerns the gene CYP19A1 and metabolic syndrome.